NCT05234736View on ClinicalTrials.gov

A Study to Evaluate the Pharmacokinetic Profile of CBL-514 Injection in Healthy Volunteers

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

February 11, 2022

Primary Completion Date

June 9, 2022

Study Completion Date

June 9, 2022

Conditions
Subcutaneous Fat
Interventions
DRUG

CBL-514

CBL-514 800 mg (unit dose: 2.0 mg/cm\^2)

Trial Locations (1)

78759

DermResearch Inc, Austin

Sponsors
All Listed Sponsors
lead

Caliway Biopharmaceuticals Co., Ltd.

INDUSTRY

NCT05234736 - A Study to Evaluate the Pharmacokinetic Profile of CBL-514 Injection in Healthy Volunteers | Biotech Hunter | Biotech Hunter